慢性肾病患儿接种肺炎球菌多糖疫苗：抗体反应及持续时间的前瞻性研究
Pneumococcal polysaccharide vaccine in children with chronic renal disease: a prospective study of antibody response and duration.
作者信息
Furth S L, Neu A M, Case B, Lederman H M, Steinhoff M, Fivush B
机构信息
Division of Pediatric Nephrology, Immunology, and Infectious Disease, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21287-2467, USA.
出版信息
J Pediatr. 1996 Jan;128(1):99-101. doi: 10.1016/s0022-3476(96)70435-3.
We studied the antibody response to pneumococcal serotypes 3 and 14 after pneumococcal polysaccharide vaccine was administered to 41 children with renal disease. One month after vaccination, 76% and 61% of patients achieved at least a twofold titer rise to serotypes 3 and 14, respectively; this finding was comparable to historic control values. One year after vaccination, the majority of patients retained protective antibody levels. Achieving a titer > or = 1.0 microgram/ml IgG at 1 month was highly predictive of retaining a protective antibody level > or = 0.15 microgram/ml at 1 year.
我们对41名肾病患儿接种肺炎球菌多糖疫苗后针对3型和14型肺炎球菌血清型的抗体反应进行了研究。接种疫苗1个月后，分别有76%和61%的患者针对3型和14型血清型的滴度至少升高了两倍；这一结果与历史对照值相当。接种疫苗1年后，大多数患者仍保持保护性抗体水平。接种后1个月时IgG滴度≥1.0微克/毫升可高度预测1年后能保持≥0.15微克/毫升的保护性抗体水平。
Zotero 插件